These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33052750)

  • 21. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
    Abramson HN
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of novel bispecific antibody therapy for multiple myeloma].
    Konishi T; Ochi T; Takenaka K
    Rinsho Ketsueki; 2024; 65(5):428-438. PubMed ID: 38825523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Novel therapies for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2024; 65(6):547-557. PubMed ID: 38960655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic progress in relapsed/refractory multiple myeloma.
    Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
    Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
    Bisht K; Fukao T; Chiron M; Richardson P; Atanackovic D; Chini E; Chng WJ; Van De Velde H; Malavasi F
    Cancer Med; 2023 Oct; 12(20):20332-20352. PubMed ID: 37840445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging agents and regimens for multiple myeloma.
    Yang Y; Li Y; Gu H; Dong M; Cai Z
    J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell exhaustion in multiple myeloma.
    Żyłka K; Kubicki T; Gil L; Dytfeld D
    Expert Rev Hematol; 2024 Jul; 17(7):295-312. PubMed ID: 38919090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
    Leleu X; Martin T; Weisel K; Schjesvold F; Iida S; Malavasi F; Manier S; Chang-Ki Min ; Ocio EM; Pawlyn C; Perrot A; Quach H; Richter J; Spicka I; Yong K; Richardson PG
    Ann Hematol; 2022 Oct; 101(10):2123-2137. PubMed ID: 35943588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of bispecific antibodies and CAR-T therapies in multiple myeloma.
    Szlasa W; Dybko J
    Int Immunopharmacol; 2024 Jun; 134():112043. PubMed ID: 38733817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
    Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.
    St Martin Y; Franz JK; Agha ME; Lazarus HM
    Blood Rev; 2023 Jul; 60():101095. PubMed ID: 37173224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Novel Immunotherapies for Multiple Myeloma.
    Al-Hujaily EM; Oldham RA; Hari P; Medin JA
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
    Perez de Acha O; Reiman L; Jayabalan DS; Walker ZJ; Bosma G; Keller AL; Parzych SE; Abbott D; Idler BM; Ribadeneyra D; Niesvizky R; Forsberg PA; Mark TM; Sherbenou DW
    Blood Adv; 2023 Nov; 7(21):6430-6440. PubMed ID: 37648670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
    Song J; Fu R
    J Clin Lab Anal; 2021 Dec; 35(12):e23832. PubMed ID: 34752645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
    Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; Ye JC; Sidhana S; Merlini G; Martin T; Lin Y; Chari A; Popat R; Kaufman JL;
    Lancet Oncol; 2024 May; 25(5):e205-e216. PubMed ID: 38697166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
    Caraccio C; Krishna S; Phillips DJ; Schürch CM
    Front Immunol; 2020; 11():501. PubMed ID: 32391000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibodies in the Treatment of Multiple Myeloma.
    van de Donk NWCJ; Zweegman S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.